This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.



William M. Glazer, M.D., and Jerrold F. Rosenbaum, M.D.

Published: September 1, 1998

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Like many other areas of medicine, psychiatry currently faces the challenge of ensuring optimal care and enhancingquality of life for patients while working within the financial constraints introduced by trying to balancecompeting needs among different sectors of the population. This challenge is particularly salient in the treatment ofdepression in a managed care setting. As an issue that demands simultaneous consideration from clinical, economic,social, and ethical perspectives, this topic raises difficult questions with regard to deciding the psychiatrist’s role as provider and allocator, determining who should assume the burden of risk, and balancing efficacy and effectivenessof different treatments, to name just a few.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...